4F-MABP - Substance Search

Summary TheDrug.Wiki

4F-MABP is a little-studied fluorinated analogue of buphedrone first identified on the European NPS market in 2014. Animal data and seizure analyses show it acts as a dopamine and norepinephrine reuptake inhibitor comparable in potency to flephedrone. Human reports are scarce; effects resemble other short-acting cathinones with rapid onset euphoria, strong urge to redose, and an uncomfortable crash.

Dose Information TheDrug.Wiki

Light Common Strong Heavy

Onset, Duration & After-effects TheDrug.Wiki

ROA	Onset	Comeup	Peak	Offset	After Effects
Oral	15-30 min	30-45 min	1-2 hrs	1-2 hrs	2-6 hrs
Insufflated	2-5 min	10-20 min	30-90 min	30-60 min	2-6 hrs

Effect Profile

Scores (1–10) curated from multiple sources:

Effect keyword matching from PsychonautWiki catalog
Weighted by importance: core (×3), major (×2), minor (×1)

Full methodology

Stimulant 4.1

Moderate 4/10

Strong anxiety/jitters with moderate euphoria, mild focus, low stimulation

Stimulation / Energy ×3

3

stimulation

Euphoria / Mood Lift ×2

7

euphoria cognitive euphoria motivation enhancement

Focus / Productivity ×2

5

focus enhancement motivation enhancement

⚠ Anxiety / Jitters ×1

10

anxiety teeth grinding increased heart rate vasoconstriction jaw clenching

Based on reports from:

Erowid Experience Reports PsychonautWiki 4F-MABP

Tolerance

Build-up develops rapidly, often within a single session; compulsive redosing common

Reset a few days for acute tolerance

Tolerance Decay

Full tolerance 2d Half tolerance 7d Baseline ~14d

Anecdotal stimulant patterns suggest rapid tolerance accrual over 1–3 days with partial reversal over 1–2 weeks of abstinence. Avoid back‑to‑back days; schedule at least 7–14 days between sessions to reduce escalation and comedown severity.